

ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES

VACCINES FOR CHILDREN PROGRAM

VACCINES TO PREVENT PNEUMOCOCCAL DISEASE

The purpose of this resolution is to update recommendations regarding the use of this vaccine in PCV13-naïve children aged 6-18 years.

VFC resolution 6/10-1 is repealed and replaced by the following:

A. Pneumococcal Conjugate Vaccine to Prevent Pneumococcal Disease

Eligible groups

- *All children at least six weeks through 59 months of age and children 60 through 71 months with certain underlying medical conditions listed in the table below.*
- *Children 6 through 18 years of age who are at increased risk for invasive pneumococcal disease because of anatomic or functional asplenia, including sickle cell disease, HIV-infection or other immunocompromising condition, cochlear implant, or cerebrospinal fluid leak.*

Table 1. Underlying medical conditions that are indications for pneumococcal vaccination among children

Immunocompetent persons	Chronic heart disease*
	Chronic lung disease**
	Diabetes mellitus
	Cerebrospinal fluid leaks
	Cochlear implant
Functional or anatomic asplenia	Sickle cell disease (SCD) and other hemoglobinopathies Congenital or acquired asplenia, or splenic dysfunction
Immunocompromised persons	HIV infection
	Chronic renal failure and nephrotic syndrome
	Diseases associated with immunosuppressive chemotherapy, or radiation therapy including malignant neoplasms, leukemias, lymphomas and Hodgkin disease; or solid organ transplantation
	Congenital immunodeficiency***
* Particularly cyanotic congenital heart disease and cardiac failure	
** Including asthma if treated with high-dose oral corticosteroid therapy	
*** Includes B- (humoral) or T-lymphocyte deficiency; complement deficiencies, particularly C1, C2, C3, and C4 deficiency; and phagocytic disorders (excluding chronic granulomatous disease)	

Recommended Pneumococcal Conjugate Vaccine Schedule and Dosage Intervals

Table 2. Recommended schedules for administering doses of PCV13 among children who have not previously received PCV7 or PCV13, those incompletely vaccinated with PCV7 or PCV13 for age, and supplemental PCV13 immunization

Age	Vaccination history: total number of PCV7 and/or PCV13 doses received previously	Recommended PCV13 Regimen ¹
2–6 mo	0 doses	3 doses, 8 weeks apart; fourth dose at age 12–15 mos
	1 dose	2 doses, 8 weeks apart; fourth dose at age 12–15 mos
	2 doses	1 dose, 8 weeks after the most recent dose; fourth dose at age 12-15 mos
7–11mo	0 doses	2 doses, 8 weeks apart; third dose at 12-15 mos
	1 or 2 doses before age 7 mo	1 dose at age 7–11 mos, with a second dose at 12–15 mos (≥ 8 weeks later)
12–23 mo	0 doses	2 doses, ≥ 8 weeks apart
	1 dose before age 12 mo	2 doses, ≥ 8 weeks apart
	1 dose at ≥ 12 mo	1 dose, ≥ 8 weeks after the most recent dose ²
	2 or 3 doses before age 12 mo	1 dose, ≥ 8 weeks after the most recent dose ²
	4 doses of PCV7 or other age-appropriate complete PCV7 schedule	1 supplemental dose, ≥ 8 weeks after the most recent dose*
24–59 mo		
Healthy children	Any incomplete schedule	1 dose, ≥ 8 weeks after the most recent dose ²
	4 doses of PCV7 or other age-appropriate complete PCV7 schedule	1 supplemental dose, ≥ 8 weeks after the most recent dose*

24- 71 mo		
Children with underlying medical conditions as defined in Table 1 ³	Any incomplete schedule of ≤ 2 doses	2 doses, one ≥ 8 weeks after the most recent dose and another dose ≥ 8 weeks later
	Any incomplete schedule of 3 doses	1 dose, ≥ 8 weeks after the most recent dose
	4 doses of PCV7 or other age-appropriate complete PCV7 schedule	1 supplemental dose, ≥ 8 weeks after the most recent dose*
6-18 years		
Children who are at increased risk for invasive pneumococcal disease as defined in footnote 4.	Not previously vaccinated with PCV 13	1 dose

Footnotes:

- 1) Minimum interval between doses is 8 weeks except for children vaccinated at age <1 year, for whom minimum interval between doses is 4 weeks.
- 2) No additional PCV13 doses are indicated for children 12 through 23 months of age who have received 2 or 3 doses of PCV7 before age 12 months and at least 1 dose of PCV13 at age 12 months or older.
- 3) For children with underlying medical conditions (see Table 1), PCV13 is indicated through 71 months of age.
- 4) Includes children with anatomic or functional asplenia, including sickle cell disease, HIV-infection or other immunocompromising condition, cochlear implant, or cerebrospinal fluid leak.

* A single supplemental dose of PCV13 given at least 8 weeks after the last dose of PCV7 is recommended for all children 14 through 59 months of age who have received 4 doses of PCV7 or other age-appropriate, complete PCV7 schedule (fully vaccinated with PCV7). For children who have underlying medical conditions, a supplemental dose is recommended through 71 months of age.

Recommended dosage

Refer to product package inserts.

Contraindications and Precautions

Contraindications and precautions can be found at:

<https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5911a1.htm>

B. 23-valent Pneumococcal Polysaccharide Vaccine (PPSV23) after PCV7 or PCV13 to Prevent Pneumococcal Disease

Eligible groups

Children and adolescents 2 through 18 years with certain underlying medical conditions listed in Table 1 above or children 2 through 18 years who are Alaska Native or American Indian.

Recommended Pneumococcal Polysaccharide Vaccine Schedule and Dosage Intervals

Table 3. Schedule for vaccination with PPSV23 after PCV13 for children ≥ 2 years of age with underlying medical conditions*

Group	Schedule for PPSV23	Revaccination with PPSV23
Children who are immunocompromised,** have sickle cell disease, or functional or anatomic asplenia	1 dose of PPSV23 administered at age ≥ 2 yrs and ≥ 8 weeks after last indicated dose of PCV13	1 dose 5 years after the first dose of PPSV23
Immunocompetent** children with chronic illness	1 dose of PPSV23 administered at age ≥ 2 yrs and ≥ 8 weeks after last indicated dose of PCV13	Not recommended

*Doses of PCV13 should be completed before PPSV23 is given. No more than two PPSV23 doses are recommended.

**See Table 1 for definitions of immunocompromised and immunocompetent with chronic illness.

Recommended dosage

Refer to product package inserts.

Contraindications and Precautions

Contraindications and precautions can be found at:

<https://www.cdc.gov/mmwr/preview/mmwrhtml/rr4909a1.htm>.

[If an ACIP recommendation regarding pneumococcal vaccination is published within 12 months following this resolution, the relevant language above (except in the eligible groups sections) will be replaced with the language in the recommendation and incorporated by reference to the publication URL.]

Adopted and Effective: February 20, 2013

This document can be found on the CDC website at:

<https://www.cdc.gov/vaccines/programs/vfc/providers/resolutions.html>